Eli Lilly and Company partnered with AI firm insitro. They announced advanced machine learning models are now accessible to select biotech companies. These models predict small molecule properties via Lilly TuneLab.
Lilly's proprietary preclinical data, spanning decades and hundreds of thousands of molecules, trained these models. The models offer a powerful tool for drug discovery.
The initiative aims to provide smaller companies with enterprise-grade predictive capabilities. This could accelerate new medicine development. It also supports the reduction of animal testing.
This move aligns with Lilly's broader strategy. Lilly aims to engage the early-stage biotech ecosystem by providing access to its resources and expertise.